Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kurt D Christensen

Showing results (1-10 of 92) with videos related to

Pageof 10
Sort By:
Personalized Medicine|December 10, 2013
How could disclosing incidental information from whole-genome sequencing affect patient behavior?Kurt D Christensen, Robert C Green
Journal of Personalized Medicine|December 23, 2015
Assessing the Costs and Cost-Effectiveness of Genomic SequencingKurt D Christensen, Dmitry Dukhovny, Uwe Siebert, et al.
Frontiers in Pharmacology|April 29, 2026
Opportunities to improve open All of Us data to convey CYP2D6 pharmacological relevance and interpretation overall and according to ancestryRachele M Hendricks-Sturrup, Kurt D Christensen, Christine Y Lu
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 19, 2018
Cost Analyses of Genomic Sequencing: Lessons Learned from the MedSeq ProjectKurt D Christensen, Kathryn A Phillips, Robert C Green, et al.
NPJ Genomic Medicine|May 17, 2024
Evaluating the utility of multi-gene, multi-disease population-based panel testing accounting for uncertainty in penetrance estimatesJane W Liang, Kurt D Christensen, Robert C Green, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|January 29, 2011
Changes to perceptions of the pros and cons of genetic susceptibility testing after APOE genotyping for Alzheimer disease riskKurt D Christensen, J Scott Roberts, Wendy R Uhlmann, et al.
Annual Review of Genomics and Human Genetics|September 6, 2013
Communicating genetic risk information for common disorders in the era of genomic medicineDenise M Lautenbach, Kurt D Christensen, Jeffrey A Sparks, et al.
Journal of Genetic Counseling|April 27, 2023
Public perspective on medications to delay Alzheimer's disease symptomsMatthew B Rich, Carrie L Blout Zawatsky, Joseph J Botta, et al.
Pharmacoeconomics - Open|October 3, 2024
Modernizing Newborn Screening in the Genomic Era: Importance of Health-Related Quality of LifeEllen Kim DeLuca, Ann Chen Wu, Kurt D Christensen, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|May 17, 2007
Providers' knowledge of genetics: A survey of 5915 individuals and families with genetic conditionsErin K Harvey, Chana E Fogel, Mark Peyrot, et al.
Pageof 10

Showing results (1-10 of 92) with videos related to

Sort By:
Pageof 10
Personalized Medicine|December 10, 2013
How could disclosing incidental information from whole-genome sequencing affect patient behavior?Kurt D Christensen, Robert C Green
Journal of Personalized Medicine|December 23, 2015
Assessing the Costs and Cost-Effectiveness of Genomic SequencingKurt D Christensen, Dmitry Dukhovny, Uwe Siebert, et al.
Frontiers in Pharmacology|April 29, 2026
Opportunities to improve open All of Us data to convey CYP2D6 pharmacological relevance and interpretation overall and according to ancestryRachele M Hendricks-Sturrup, Kurt D Christensen, Christine Y Lu
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 19, 2018
Cost Analyses of Genomic Sequencing: Lessons Learned from the MedSeq ProjectKurt D Christensen, Kathryn A Phillips, Robert C Green, et al.
NPJ Genomic Medicine|May 17, 2024
Evaluating the utility of multi-gene, multi-disease population-based panel testing accounting for uncertainty in penetrance estimatesJane W Liang, Kurt D Christensen, Robert C Green, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|January 29, 2011
Changes to perceptions of the pros and cons of genetic susceptibility testing after APOE genotyping for Alzheimer disease riskKurt D Christensen, J Scott Roberts, Wendy R Uhlmann, et al.
Annual Review of Genomics and Human Genetics|September 6, 2013
Communicating genetic risk information for common disorders in the era of genomic medicineDenise M Lautenbach, Kurt D Christensen, Jeffrey A Sparks, et al.
Journal of Genetic Counseling|April 27, 2023
Public perspective on medications to delay Alzheimer's disease symptomsMatthew B Rich, Carrie L Blout Zawatsky, Joseph J Botta, et al.
Pharmacoeconomics - Open|October 3, 2024
Modernizing Newborn Screening in the Genomic Era: Importance of Health-Related Quality of LifeEllen Kim DeLuca, Ann Chen Wu, Kurt D Christensen, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|May 17, 2007
Providers' knowledge of genetics: A survey of 5915 individuals and families with genetic conditionsErin K Harvey, Chana E Fogel, Mark Peyrot, et al.
Pageof 10